British American Tobacco (BATS) H1 2026 earnings summary
Event summary combining transcript, slides, and related documents.
H1 2026 earnings summary
30 Jul, 2026Executive summary
H1 2026 results met expectations, with revenue up 2.9% at constant FX and adjusted profit from operations up 3.5%, driven by strong U.S. multi-category and New Category performance.
Smokeless product consumers increased by 4.1 million to 35 million, now representing 19.8% of group revenue.
New Category contribution rose 55% at constant rates to £269m, with Modern Oral up 65.9% and strong Velo and Vuse performance.
Resilient combustibles performance, especially in the U.S. and AME, supported by cost-saving initiatives.
Transformation momentum is evident, with continued strong cash returns and on track for leverage corridor of 2.0-2.5x by year-end.
Financial highlights
Group revenue: £12,235m (+2.9% constant FX, +1.4% reported); New Categories revenue: £1,928m (+18% constant FX).
Adjusted profit from operations: £5,319m (+3.5%); adjusted operating margin: 43.7% (+30bps, as adjusted for Canada).
Adjusted diluted EPS up 7.9% to 164.0p (as adjusted for Canada).
Adjusted gross profit increased 3.8% to £8.3bn; category contribution margin (New Categories) up to 13.8%.
Net cash from operating activities up 47.3% to £3,402m; free cash flow pre-dividend up 85.2% to £2,285m.
Outlook and guidance
FY26 guidance reaffirmed: 3-5% revenue growth, mid-teens New Category revenue growth, 4-6% adjusted profit from operations growth (H2 weighted).
Adjusted diluted EPS growth expected toward the middle of 5-8% guidance range.
Operating cash flow conversion expected to exceed 95%; leverage to be within 2.0-2.5x corridor.
Commitment to progressive dividend and £1.3bn share buy-back for FY26.
Gross capital expenditure for 2026 expected at ~£750m.
Latest events from British American Tobacco
- New category growth and cost discipline offset regulatory and illicit trade headwinds in 2024.BATS
H2 202420 Jul 2026 - H1 revenue up 1.8% at constant FX, led by Modern Oral and U.S. growth; profit up 19.1%.BATS
H1 20258 Jul 2026 - Mid-teens revenue growth led by Modern Oral and Vapour, with robust U.S. and cash generation momentum.BATS
Trading update2 Jun 2026 - FY25 delivered top-end results, led by Modern Oral and New Category growth, strong U.S. and AME performance.BATS
H2 202513 Apr 2026 - Accelerating smokeless transformation and U.S. growth through innovation and regulatory action.BATS
Consumer Analyst Group of New York Conference (CAGNY) 202619 Feb 2026 - New Category growth and innovation offset U.S. headwinds, supporting full-year guidance.BATS
H1 20243 Feb 2026 - Guidance reaffirmed as new categories and innovation drive H2 acceleration and cash returns.BATS
Trading Update31 Jan 2026 - Accelerating innovation and smokeless growth, with robust financials and U.S. market stabilization.BATS
21st Annual dbAccess Global Consumer Conference 202431 Jan 2026 - Accelerates smokeless transformation, targeting >50% revenue from new categories by 2035.BATS
CMD 202419 Jan 2026